Related Experiment Video
Updated: Dec 13, 2025
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
11.8K
Long-term outcome in multiple sclerosis patients treated with fingolimod
Simona Lattanzi1, Chiara Rocchi1, Maura Danni1
1Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60020 Ancona, Italy.
Multiple Sclerosis and Related Disorders
|July 30, 2020
Summary
Fingolimod (FTY) treatment shows potential for long-term management of relapsing-remitting multiple sclerosis (RRMS). Patients with less disability and fewer prior relapses may experience better disease control with FTY.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Ongoing disease activity in Multiple Sclerosis (MS) correlates with worse disability outcomes.
- Assessing long-term treatment effectiveness is crucial for managing MS.
Purpose of the Study:
- To evaluate the 5-year efficacy of fingolimod (FTY) in patients with relapsing-remitting MS (RRMS) within a real-world clinical setting.
- To identify predictors of treatment response to FTY in RRMS patients.
Main Methods:
- A cohort of RRMS patients receiving FTY for at least 6 months with a minimum 60-month follow-up was analyzed.
- Treatment response was determined by the No Evidence of Disease Activity (NEDA)-3 status.
Main Results:
- Among 88 RRMS patients, 55.9% of fingolimod-naïve patients and 35.0% of those switching from other treatments maintained NEDA-3 status at 5 years.
- Lower baseline Expanded Disability Status Scale scores predicted NEDA-3 status in fingolimod-naïve patients.
- Fewer relapses in the 12 months prior to FTY initiation predicted NEDA-3 status in treatment-switching patients.
Conclusions:
- Fingolimod (FTY) demonstrates potential as a long-term disease-modifying therapy for RRMS.
- Early treatment in patients with milder disability and fewer relapses may lead to improved long-term disease control in RRMS.
